Status:
COMPLETED
Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Europe and Asia. The aim of this observational study is to evaluate the effectiveness and the incidence of serious adverse reactions while using Levemir®, NovoMix® and/or No...
Eligibility Criteria
Inclusion
- Any insulin näive type 2 diabetic patient that able to use the drug as judged by the investigator
Exclusion
- In accordance with approved label
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
10408 Patients enrolled
Trial Details
Trial ID
NCT00771680
Start Date
October 1 2008
End Date
July 1 2010
Last Update
October 28 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Moscow, Russia, 119330
2
Novo Nordisk Investigational Site
Kiev, Ukraine, 252030